Skip to main content
KIDS logo

KIDS · Orthopediatrics Corp · Financials

Track KIDS — free
$31.74 -0.77 (-2.37%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$828.75M
Shares
26.11M
Volume · Nov 20 153.14K Avg daily vol (3M) 276.7K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$236.35M +15.4%
FY2025 Revenue FY2015–FY2025
Net Income
-$39.65M -4.8%
FY2025 Net Income FY2015–FY2025
Gross Margin
73.05% +0.5pp
FY2025 Gross Margin FY2015–FY2025
Operating Margin
-16.6% +0.5pp
FY2025 Operating Margin FY2015–FY2025
Diluted EPS
-$1.69 -3%
FY2025 Diluted EPS FY2019–FY2025
Operating Cash Flow
-$4.85M +82.1%
FY2025 Operating Cash Flow FY2015–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015
$270M – $273M $264.14M $236.35MG $204.73MG $148.73MG $122.29MG $98.05MG $71.08M $72.55M $57.56M $45.62M $37.3M $31M
— — — — $198K -$2.42M -$2.25M -$3.41M -$3.54M — — — —
— $69.3M $63.69M $56.13M $37.48M $31.63M $24.65M $16.05M $17.93M $14.88M $11.17M $10.93M $9.37M
— $194.84M $172.66M $148.6M $111.25M $90.66M $73.4M $55.03M $54.62M $42.68M $34.45M $26.37M $21.64M
— — 73.05% 72.58% 74.8% 74.14% 74.86% 77.42% 75.28% 74.15% 75.52% 70.69% 69.79%
— $9.28M $9.1M $11.03M $10.9M $8.45M $5.54M $5.27M $5.75M $4.73M $3.42M $2.22M $1.79M
— $81.26M $72.73M $64.3M $52.82M $46.09M $39.67M $31.85M $31.28M $26.56M $20.53M $16.66M $15.03M
— $125.82M $119.83M $102.79M $73.3M $57.9M $46.06M $38.32M $26.66M $20.94M $16.97M $11.63M $11.41M
— — $8.17M $7.81M $7.15M $5.98M $4.53M $3.25M $887K $378K $246K $35K $6000
— $22.65M $21.12M $19.08M $17.39M $13.1M $10.68M $8.01M $4.67M $2.89M $2.41M $1.9M $1.85M
— — $5.6M $3.65M $0 — — — — — — — —
— $219.64M $211.9M $183.61M $138M $116.06M $91.43M $81.79M $63.7M $52.23M $40.92M $32.49M $28.23M
— -$24.8M -$39.24M -$35.01M -$26.75M -$25.4M -$18.02M -$26.76M -$9.08M -$9.55M -$6.47M -$6.13M -$6.59M
— — -16.6% -17.1% -17.99% -20.77% -18.38% -37.64% -12.51% -16.6% -14.19% -16.43% -21.26%
— -$2.15M -$18.12M -$15.93M -$9.37M -$12.3M -$7.34M -$18.75M -$4.41M -$6.66M -$4.07M -$4.23M -$4.74M
— $9.18M $6M $2.62M -$198K $2.42M — $3.41M $3.54M $2.26M $2.49M $1.48M $1.23M
— -$8.79M $50K -$6.92M $5.44M $21.71M $636K -$6.91M -$3.61M -$2.47M -$2.46M -$445K -$1.26M
— -$33.59M -$39.19M -$41.93M -$21.31M -$3.69M -$17.39M -$33.67M -$12.69M -$12.03M -$8.95M — —
— $294K $460K -$4.11M -$338K -$4.95M -$1.13M -$723K $0 $0 $0 $0 $0
— -$33.88M -$39.65M -$37.82M -$20.97M $1.26M -$16.26M -$32.94M -$13.73M -$12.03M -$8.93M -$6.57M -$7.89M
— — -16.78% -18.47% -14.1% 1.03% -16.58% -46.35% -18.93% -20.89% -19.58% -17.62% -25.45%
— — -$39.65M -$37.82M -$20.97M $1.24M -$16.26M -$32.94M -$13.73M -$12.03M -$23.53M -$12.45M -$12.69M
— -$29.22M -$29.4M -$43.07M -$21.1M -$12.63M -$15.68M -$25.03M -$13.11M -$12.78M -$8.8M -$6.57M -$7.89M
USD/shares — -$1.43 -$1.69 -$1.64 -$0.92 $0.06 -$0.84 -$1.82 -$0.94 — — — —
USD/shares — -$1.43 -$1.69 -$1.64 -$0.92 $0.06 -$0.84 -$1.82 -$0.94 — — — —
shares — — 23.46M 23.08M 22.68M 20.7M 19.27M 18.06M 14.62M 12.57M 4.02M 1.74M 1.74M
shares — — 23.46M 23.08M 22.68M 20.95M 19.27M 18.06M 14.62M 12.57M 4.02M 1.74M 1.74M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2015–FY2019: $5.97M in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Long-term debt, including current maturities 2026-09-30 USD 104,605,000 10-Q filed 2026-10-28
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of long-term debt
USD 2,938,000
Noncurrent convertible notes payable
USD 48,961,000
Noncurrent debt carrying amount
USD 98,188,000
Noncurrent other long-term debt
USD 515,000
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Some debt data could not be processed yet.
1 filing has incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

4.75% Convertible Senior Notes due February 15, 2030

Note · OrthoPediatrics Corp.

Reference: 4.75% Convertible Senior Notes due February 15, 2030

Active
Original principal
USD 50,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
Feb 15, 2030

Last reported interest terms: 4.75% Reported 2024-08-12 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2024-08-12 Original principal USD 50,000,000 Exact source document Parent 8-K filing · 2024-08-12
    Also on August 12, 2024, the Company issued $50.0 million in aggregate principal amount of the Company’s 4.75% Convertible Senior Notes due February 15, 2030 (the “Notes”) pursuant to the previously announced Purchase Agreement (the “Purchase Agreement”), dated August 5, 2024, by and between the Company and Braidwell Transaction Holdings LLC – Series 10 (the “Purchaser”). The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of August 12, 2024, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). The Indenture and form of Notes are also filed as Exhibits 4.1 and 4.2 hereto, and are incorporated herein by reference.
    Issuer evidence: On August 12, 2024, the previously announced Credit Agreement and Guaranty (the “Term Loan Agreement”), dated August 5, 2024, by and among OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers, one or more funds managed by Braidwell LP, as lenders, and Wilmington Trust, National Association, as agent, was closed and the $25,000,000 Initial Term Loan Commitment was funded.
    Supporting evidence: Also on August 12, 2024, the Company issued $50.0 million in aggregate principal amount of the Company’s 4.75% Convertible Senior Notes due February 15, 2030 (the “Notes”) pursuant to the previously announced Purchase Agreement (the “Purchase Agreement”), dated August 5, 2024, by and between the Company and Braidwell Transaction Holdings LLC – Series 10 (the “Purchaser”). The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of August 12, 2024, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). The Indenture and form of Notes are also filed as Exhibits 4.1 and 4.2 hereto, and are incorporated herein by reference.

Term Loan Agreement

TermLoan · OrthoPediatrics Corp.

Reference: Term Loan Agreement

Active
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Reported commitment: USD 25,000,000 Reported 2024-08-12 Disclosed facility capacity; the amount drawn and capacity available today are not established.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2024-08-12 Commitment USD 25,000,000 Exact source document Parent 8-K filing · 2024-08-12
    On August 12, 2024, the previously announced Credit Agreement and Guaranty (the “Term Loan Agreement”), dated August 5, 2024, by and among OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers, one or more funds managed by Braidwell LP, as lenders, and Wilmington Trust, National Association, as agent, was closed and the $25,000,000 Initial Term Loan Commitment was funded.
    Issuer evidence: On August 12, 2024, the previously announced Credit Agreement and Guaranty (the “Term Loan Agreement”), dated August 5, 2024, by and among OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers, one or more funds managed by Braidwell LP, as lenders, and Wilmington Trust, National Association, as agent, was closed and the $25,000,000 Initial Term Loan Commitment was funded.
    Supporting evidence: On August 12, 2024, the previously announced Credit Agreement and Guaranty (the “Term Loan Agreement”), dated August 5, 2024, by and among OrthoPediatrics Corp. (the “Company”) and its wholly owned domestic subsidiaries, as borrowers, one or more funds managed by Braidwell LP, as lenders, and Wilmington Trust, National Association, as agent, was closed and the $25,000,000 Initial Term Loan Commitment was funded.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
3.35×
Peer median 3.14×
EV/EBIT
—
Peer median 23.15×
P/E (TTM)
—
Peer median 27.38×
Price/Sales (TTM)
3.14×
Peer median 3.02×
Price/Book
2.44×
Peer median 3.57×
EV/Adj. EBITDA (FY2025)
60.01×
Peer median 11.27×

Peer medians compare against the 65 similar-size Medical Devices companies (of 164 listed).

EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.

Valuation over time computed as of each quarter's filing date

EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
United States $186,403,000 $161,163,000 $111,010,000 $92,419,000 $77,781,000 $62,966,000 $55,055,000 $43,461,000
Non Us $49,945,000 $43,564,000 $37,722,000 $29,870,000 $20,268,000 $8,112,000 $17,497,000 $14,098,000

By Product & Service (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Trauma and Deformity $166,301,000 $145,126,000 $106,781,000 $85,055,000 $65,829,000 $47,677,000 $49,371,000 $39,695,000
Spine $66,047,000 $55,153,000 $37,933,000 $33,428,000 $28,046,000 $20,738,000 $21,485,000 $16,662,000
Sports Medicine and Other $4,000,000 $4,448,000 $4,018,000 $3,806,000 $4,174,000 $2,663,000 $1,696,000 $1,202,000
Key facts CIK 1425450 CUSIP 68752L100 13F (30d) 139 filings 123 filers Visit website Investor relations